The Golden trial is a study of a potential new treatment referred to as ISIS 696844 to determine its safety and effectiveness in slowing the progression of geographic atrophy (GA) caused by age-related macular degeneration (AMD).
About this study
Geographic atrophy (GA) is a late stage of age-related macular degeneration (AMD) and occurs when cells in the retina deteriorate and die, resulting in blind spots in the visual fields.
This trial assesses the safety and efficacy of IONIS-FB-LRx in participants with GA secondary to AMD.
The investigational drug was administered via subcutaneous injection beneath the skin in abdomen or thigh – not into the eye. Because of this, there was the potential to treat both eyes with just one single injection.
Ethics
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.
The Clinical Trials Centre (CTC) is a dedicated, purpose-built space where we conduct clinical trials.
The CTC is located on Level 2 South. When you arrive, if you are unsure where to go, talk to one of our friendly volunteers or the information desk staff.